step is to implement some actions that can minimize the highlighted risks. The paper from Vrignaud's team will be of help for all those pharmacists intending to set-up a risk analysis for the production of parenteral nutrition bags. It can also be a wider risk-analysis guide for all injectables produced in compounding pharmacies.
A pharmacist is also the qualified person to guarantee the expiration date and the quality of a prepared drug product. To do so, a stability study has to be performed if no specific data can be found in a database such as Stabilis (http://www.stabilis.org) a free international website managed by Dr. Jean Vigneron. In this issue we have two examples of stability studies performed on injectable solutions. The first one is from the team of Irene Krämer in Mainz, Germany and demonstrates the stability of Mozobil® (active drug: plerixafor) solution along three months. This result is important because it allows potential important cost savings in central pharmacies. The second study from Thomas Briot in Angers, France demonstrates the very limited stability of mitomycin C diluted solutions. This results shows that a good cooperation between pharmacy department and the wards is mandatory in this case, in order to limit the delay between the prescription and the administration to the patient. Those two studies show the importance of stability studies in our professional field. These types of work can be significant to find the best organization for providing the in-pharmacy prepared product to the wards while assuring their quality. It is also a way to prevent wastage and to obtain high cost savings because the prices of the drug vials can be very high. This data can finally be very useful for pharmacists to help them to determine the date of expiry of their prepared products. However, to be reliable, those stability studies have to be performed following good laboratory practice and specific guidelines as the ones published by the GERPAC experts and available online (http://www.gerpac.eu/ IMG/pdf/guide_stabilite_anglais.pdf). Our journal will always be keen to publish well-performed stability studies in the future because we know how useful they are for pharmacists, because materials and qualified persons *Corresponding author: Frederic Lagarce, Department of Pharmacy, CHU Angers, 4 rue Larrey, 49033 Angers, France; University of Angers, Angers, France, E-mail: frederic.lagarce@univ-angers.fr to perform those studies are not present in all hospital pharmacies.
The last paper of this second issue is a review article on the particulate matter in injection and their related risks to patients. Very often, for injectable drugs, a focus is put on the microbiological contamination because those formulations have to remain sterile. The question of the presence of particles is as important because the risks for the patient can be critical. The paper describes the source of particles in the injectable formulation and some particle characteristics such as size, shape or electrical charge having a potential impact on patient safety.
In conclusion, this second issue of PTHP reflects the variety of technologies applied to hospital pharmacy. Many questions and issues remain to be addressed in this field to improve or assure the quality of therapeutics for the patients. This looks very promising for the future dynamics of our journal.
